𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease

✍ Scribed by Amy J. Bastian; Valerie E. Kelly; Joel S. Perlmutter; Jonathan W. Mink


Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
135 KB
Volume
18
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

We examined the effects of levodopa and unilateral pallidotomy on quantitative measures of walking and reaching in Parkinson's disease (PD). We also compared quantitative measures of movement with standard clinical rating scales. We used kinematic measures and the Unified Parkinson's Disease Rating Scale (UPDRS) motor subscale (subscale III) to evaluate the movement of 10 people with PD. Subjects were tested after withholding PD medications for at least 8 hours and again 30 to 45 minutes after taking the first morning dose of levodopa. They were studied in this manner before unilateral pallidotomy and then 3.5 to 10 months after surgery. The UPDRS motor subscale was performed in each state. Kinematic data were collected as subjects reached to a target and walked. The UPDRS motor subscale ratings were similar to those reported in the literature: pallidotomy improved the overall motor score and the contralateral bradykinesia + rigidity score, but not the gait + posture score. In contrast, kinematic measures demonstrated that levodopa and pallidotomy had different effects on walking and reaching speed. Both treatments improved walking speed, and the effect was additive. Levodopa improved reaching speed before pallidotomy but did not improve it as much after pallidotomy. Additionally, pallidotomy had inconsistent effects on reaching; some subjects were faster and others were slower. The subjects who initially reached more slowly improved after pallidotomy; the subjects who initially reached more normally (faster) worsened after pallidotomy. On the basis of our results, we speculate that basal ganglia output pathways that control walking and reaching may be distinct, such that bilateral projections to the pedunculopontine area influence walking, whereas ipsilateral thalamocortical projections influence reaching. Β© 2003 Movement Disorder Society


πŸ“œ SIMILAR VOLUMES


Interaction of levodopa and cues on volu
✍ Valerie E. Kelly; Allie S. Hyngstrom; Melissa M. Rundle; Amy J. Bastian πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 165 KB πŸ‘ 1 views

## Abstract The bradykinesia associated with Parkinson's disease (PD) can be improved by both levodopa and the use of external cues. We examined the combined effect of levodopa and external cueing on the voluntary reaching movements of individuals with PD. Nine subjects with PD and nine matched con

Effects of unilateral pallidotomy on vol
✍ Ryoichi Hayashi; Takao Hashimoto; Tsuyoshi Tada; Shu-ichi Ikeda πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 157 KB πŸ‘ 1 views

## Abstract We studied the effects of unilateral pallidotomy on motor execution and reaction times in patients with moderately advanced Parkinson's disease (PD). Twelve consecutive patients (7 men, 5 women; all right‐handed) underwent left‐side microelectrode‐guided pallidotomy. In addition to clin

Different effects of unilateral versus b
✍ Amy J. Bastian; Valerie E. Kelly; Fredy J. Revilla; Joel S. Perlmutter; Jonathan πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 100 KB

## Abstract The purpose of this study was to determine the effects of unilateral versus bilateral subthalamic nucleus (STN) stimulation on quantitative measures of walking and reaching in Parkinson's disease (PD). We used kinematic measures and the Unified Parkinson's Disease Rating Scale (UPDRS) m

Effects of levodopa and COMT inhibitors
✍ Paolo Lamberti; Stefano Zoccolella; Giovanni Iliceto; Elio Armenise; Angela Frad πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 70 KB πŸ‘ 1 views

## Abstract Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment, and dementia. Elevated plasma concentrations of Hcy have been found recently in Parkinson's disease (PD) patients treated with levodopa, suggesting that levodopa is a cause of hyperhomocysteinemia (HHcy). T